Destaques

Opinião | Os coronavírus são “espertos”: cenários evolutivos para o futuro do SARS-CoV-2.

19 Fev, 2022 | 14:01h

Coronaviruses are ‘clever’: Evolutionary scenarios for the future of SARS-CoV-2 – STAT

---

Perspectiva | Estamos entrando na fase de controle da pandemia.

19 Fev, 2022 | 13:59h

We’re Entering the Control Phase of the Pandemic – The Atlantic

---

Estudo randomizado | Darolutamida e sobrevida no câncer de próstata metastático e sensível a hormônio.

19 Fev, 2022 | 13:58h

Darolutamide and Survival in Metastatic, Hormone-Sensitive Prostate Cancer – New England Journal of Medicine

 

Comentário no Twitter

Adding darolutamide to androgen-deprivation therapy and docetaxel significantly increased overall survival among patients with metastatic, hormone-sensitive prostate cancer. #GU22 https://t.co/GkQZdKgtJs pic.twitter.com/3e5S7tW1Zw

— NEJM (@NEJM) February 17, 2022

 

---

Estimativas de prevalência global, regional e nacional da violência conjugal física ou sexual, ou ambas, contra mulheres.

19 Fev, 2022 | 13:57h

Global, regional, and national prevalence estimates of physical or sexual, or both, intimate partner violence against women in 2018 – The Lancet

Comunicado de imprensa: More than a quarter of women have experienced intimate partner violence in their lifetimes, finds new study – The Lancet

Comentário: Intimate partner violence against women: a persistent and urgent challenge – The Lancet

 

Comentário no Twitter (fio – clique para saber mais)

NEW—Over 1 in 4 women have experienced intimate partner violence in their lifetimes, study finds.

Authors highlight urgent need to strengthen the public health response in post-COVID-19 reconstruction efforts. https://t.co/yZ61fqIZlV pic.twitter.com/AeMSicRUY0

— The Lancet (@TheLancet) February 17, 2022

 

---

Estudo randomizado | Nirmatrelvir oral para adultos de alto risco com Covid-19 reduz em 89% o risco de internação.

17 Fev, 2022 | 15:37h

Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19 – New England Journal of Medicine

Entrevista em áudio: A New Antiviral against Covid-19 – new England Journal of Medicine

Conteúdos relacionados:

[Press release – not published yet] Pfizer’s Covid pill remains 89% effective for reducing the risk of hospitalization or death in final analysis.

[Press release – not published yet] RCT: Pfizer’s novel Covid-19 oral antiviral treatment candidate reduced risk of hospitalization or death by 89% in interim analysis of phase 2/3 EPIC-HR study.

Statement on potential drug-drug interactions between Ritonavir-boosted Nirmatrelvir (Paxlovid) and concomitant medications; antiarrhythmics, oral anticoagulants, immunosuppressants, anticonvulsants, antineoplastics, and neuropsychiatric drugs are among the drugs of concern.

 

Comentário no Twitter

The Paxlovid pill (Nirmatrelvir) randomized, placebo-controlled trial published @NEJM:
89% efficacy vs Covid hospitalizations or deaths, and quick reduction of viral load.
The active pills had less serious adverse events or discontinuations than placebohttps://t.co/HBMRZt4wBo pic.twitter.com/LDQv41O56c

— Eric Topol (@EricTopol) February 16, 2022

 

---

Estudo de coorte retrospectiva | Vacina da Pfizer reduz o risco de reinfecção após recuperação da Covid-19.

17 Fev, 2022 | 15:35h

Effectiveness of the BNT162b2 Vaccine after Recovery from Covid-19 – New England Journal of Medicine

 

Comentário no Twitter

Among patients who had recovered from Covid-19, the receipt of at least one dose of the BNT162b2 vaccine was associated with a significantly lower risk of recurrent infection. https://t.co/AAlsY9sFlv pic.twitter.com/Nkj1lP77ZW

— NEJM (@NEJM) February 16, 2022

 

---

Estudo de coorte | Proteção contra SARS-CoV-2 após vacinação para Covid-19 dura mais em pacientes com infecção prévia.

17 Fev, 2022 | 15:34h

Protection against SARS-CoV-2 after Covid-19 Vaccination and Previous Infection – New England Journal of Medicine

---

Inglaterra vai oferecer doses de vacina contra Covid para crianças de 5 a 11 anos de idade.

17 Fev, 2022 | 15:32h

England to offer Covid jab to five to 11-year-olds – BBC

---

Metanálise mostra que a prevalência geral de intolerância à estatina é de cerca de 9% e identifica os fatores de risco mais comuns.

17 Fev, 2022 | 15:31h

Prevalence of statin intolerance: a meta-analysis – European Heart Journal

Comentários:

Study shows the true prevalence of statin intolerance worldwide is between 6 to 10% – News Medical / European Society of Cardiology

Expert reaction to study looking at statin intolerance – Science Media Centre

Conteúdos relacionados:

Side effect patterns in a crossover trial of statin, placebo, and no treatment – This N-of-1 trial, now published in full, suggests the nocebo effect causes most of statins muscle adverse effects.

#AHA20 – In patients who had discontinued statins because of side effects, a N-of-1 trial of a statin, placebo, or no treatment found that side effects often attributed to statins were the same for those taking a placebo

 

Comentário no Twitter

Statin intolerance is “over-estimated and over-diagnosed”. World’s largest study shows less than 10% suffer side-effects caused by statins https://t.co/pcVk8YI3I3@escardio #EHJ #ESCYoung #cardiotwitter @ehj_ed @rladeiraslopes #CVD #Riskfactors pic.twitter.com/b3nFWsc74d

— European Society of Cardiology Journals (@ESC_Journals) February 16, 2022

 

---

Revisão | Diagnóstico e tratamento de síndromes coronarianas agudas.

17 Fev, 2022 | 15:29h

Diagnosis and Treatment of Acute Coronary Syndromes: A Review – JAMA (gratuito por tempo limitado)

Revisão clínica em áudio: Diagnosis and Treatment of Acute Coronary Syndromes – JAMA

---